Latest news
25 items- PROS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to PipelineConsolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d
- PRAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting ObligationsMONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Comp
- SECSEC Form 15-12G filed by Advaxis, Inc.15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form 10-K/A filed by Advaxis, Inc. (Amendment)10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECAdvaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form 10-K filed by Advaxis, Inc.10-K - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form S-8 POS filed by Advaxis, Inc.S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECAdvaxis, Inc. filed SEC Form 8-K: Leadership Update8-K - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form NT 10-K filed by Advaxis, Inc.NT 10-K - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECAdvaxis, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- PRAyala Pharmaceuticals Announces Completion of Sale of AL102 to ImmunomeMONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (NASDAQ:IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments. "We are pleased that AL102 will now be advanced by the highly experienced team at Immunome," said Ken Berlin, President and
- INSIDERSEC Form 4 filed by Israel Biotech Fund I, L.P.4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
- SECSEC Form DEFM14C filed by Advaxis, Inc.DEFM14C - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECAdvaxis, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- SECSEC Form PREM14C filed by Advaxis, Inc.PREM14C - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
- PRImmunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month – Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. Earlier this month, Immunome announced that it entered into a definitive asset purchase agreement with Ayala to acquire AL102 and related drug candidate AL101. Completion of the transaction remains subject to customary clos
- PRAyala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsREHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. "Completion of enrollment in RINGSIDE represents a significant milestone in the development of AL102," said Kenneth Berlin, President and Chief Executive Officer of Ayala. "There has been a high-level of enthusiasm from clinical trial investigators, support staff, and patients during the enrollment of RINGSIDE. We are extremely grateful to the patients and their families, cl
ADXS FAQ
6 questionsWhat does Advaxis, Inc. do?
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused...Where does ADXS stock trade?
Advaxis, Inc. (ADXS) is listed on NASDAQ.What sector and industry is ADXS in?
Advaxis, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Advaxis, Inc. go public?
Advaxis, Inc. (ADXS) completed its IPO in n/a.What companies are similar to ADXS?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare ADXS side-by-side with any of them on Quantisnow.How can I track ADXS on Quantisnow?
Quantisnow aggregates Advaxis, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADXS to receive live email and push alerts on every new disclosure.